IgG4-TREAT Systematic study of IgG4-autoimmune diseases to develop new treatment strategies
- Coordinator
- Medizinische Universitaet Wien, Austria
- Runs
- 1 September 2023 to 31 August 2027
- Status
- Running
- EU funding
- €2.6m
- Total cost
- —
- Partners
- 20 organisations in 9 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101119457
What the project is doing
In the project's own words, from its summary on CORDIS.
IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AIDhave commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutictargets and test new treatment strategies feasible and necessary.
We hypothesize that genetic risk factors and a dysregulatedimmune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a specialsubclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in thebody. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules andmechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-art cell and molecular biology methodology.
We will establish a new humanized mouse model of IgG4-AID for the developmentand testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovativetraining program combines university-based and multidisciplinary research-based training with state-of the art web-based trainingand in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translationalresearch with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for genderequality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,such as climate change, social inequalities and pandemics.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Universitaet Wien | Wien | Austria | Coordinator |
| Masarykova univerzita | Brno | Czechia | Associatedpartner |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Christian-Albrechts-Universitaet Zu Kiel | Kiel | Germany | Associatedpartner |
| Generate | Kiel | Germany | Associatedpartner |
| Universitatsklinikum Schleswig-Holstein | Lübeck | Germany | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Associatedpartner |
| Hellenic Pasteur Institute | Athens | Greece | Associatedpartner |
| Tzartos - Diagnosis & Research in Neuroimmunology Medical Limited Liability Company | Athens | Greece | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Associatedpartner |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Sorbonne Universite | Paris | France | Associatedpartner |
| Azienda Ospedaliero Universitaria Pisana | Pisa | Italy | Associatedpartner |
| Fondazione Istituto Neurologico Nazionale Casimiro Mondino | Pavia | Italy | Associatedpartner |
| Universita Di Pisa | Pisa | Italy | Associatedpartner |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Stichting Sanquin Bloedvoorziening | Amsterdam | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Associatedpartner |
| Istanbul Universitesi | Istanbul | Türkiye | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI